Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Benzer Materyaller

• Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
  Yazar:: Yoon, Hee-Young, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
  Yazar:: Yang, Hua, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
  Yazar:: Wu, Shang-Gin, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
  Yazar:: Chang, Yoon Soo, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Epidermal growth factor receptor tyrosine kinase inhibitors
  Yazar:: Ranson, M
  Baskı/Yayın Bilgisi: (2004)